Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine

Trial Start Expected In August-October

Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.

Biochemistry
Vaccine Has Part Of SARS-CoV-2 Spike Protein Coding Region Added To M2SR • Source: Shutterstock

Bharat Biotech International Ltd., one of India's leading vaccine makers, has partnered with the University of Wisconsin–Madison (UW-Madison) and US-based vaccine company FluGen Inc. to develop a COVID-19 vaccine, joining the ranks of those working to provide nations with armor to tackle the coronavirus infection.

Like several other drugs and vaccines currently being developed to combat COVID-19 respiratory disease, this candidate is also repurposed, using...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip